Rituximab: As First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular Lymphoma

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.7, 2011-05, pp. : 885-895

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab + CHOP: first-line therapy in B-cell lymphoma

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma: Long-Term Economic Evaluation

By Deconinck Eric

PharmacoEconomics, Vol. 28, Iss. 1, 2010-01 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

By Ray Joshua A. Carr Emma Lewis Gavin Marcus Robert

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 346-357

Blackwell Publishing

Access to resources Recommend Favorite

Rituximab maintenance improves outcomes in follicular lymphoma

Inpharma, Vol. 1, Iss. 1568, 2006-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

A CHOP regimen is effective for post-transplant lymphoproliferative disorders (PTLD) that have progressed after first-line therapy with rituximab

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite